Updated on December 13, 2016
December 2016 Vensun Series C Financing Press Release
Vensun Pharmaceuticals completes a $22.5 million Series C financing led by Perceptive Advisors, LLC.
February 2016 Joan Janulis Press Release
Vensun Pharmaceuticals appoints Joan Janulis as the Senior Vice President of Regulatory Affairs and Compliance
February 2016 Vensun launches the first approved product from its development portfolio – Carisoprodol Tablets, USP, 250 mg, Press Release Vensun Pharmaceuticals announces the launch of Carisoprodol Tablets, USP, 250 mg, the first generic equivalent to Meda’s Soma® 250 mg Tablets.
April 2015 Ed Schutter Press Release
Vensun Pharmaceuticals appoints Ed Schutter to its Board of Directors
October 2014 Josh Gordon Press Release
Vensun Pharmaceuticals appoints Josh Gordon as the Senior Vice President of Sales, Marketing and Commercial Operations
August 2014 Vensun ScieGen Agreement Press Release
Vensun Pharmaceuticals has entered into Manufacturing, Supply and Distribution Agreement with ScieGen Pharmaceuticals to commercialize 23 prescription generic products
Vensun Pharmaceuticals files its 20th ANDA
December 2013 Vensun Series B Financing Press Release
Vensun Pharmaceuticals completes a $15.8 million Series B financing led by JW Asset Management, LLC; Vensun Pharmaceuticals files its 10th ANDA
Vensun Pharmaceuticals executes a multi-product development & supply agreement with a Bengaluru, India based FDA approved pharmaceutical company.
Vensun Pharmaceuticals raises $5.7M in a Series A financing led by JW Asset Management. The company is now established as a Delaware C corp – Vensun Pharmaceuticals, Inc.
Vensun Pharmaceuticals executes a multi-product Development & Supply Agreement with a leading Chennai, India based FDA approved pharmaceutical company.
Vensun Pharmaceuticals files its 1st ANDA
Vensun Pharmaceuticals raises an initial funding of $1.68M
Vensun Pharmaceuticals executes a multi-product Development and Supply Agreement with Pharmaceutics International, Inc. (Pii); Vensun Pharmaceuticals, LLC is established as a rapidly emerging pharmaceutical company developing a unique portfolio of generic prescription products in various dosage forms covering a broad range of therapeutic categories.